ER, PR,HER 2

ER, PR,HER 2 Test

The ER, PR, HER2 test is a group of biomarker tests commonly performed on breast cancer tissue to identify specific receptors and proteins present in cancer cells. The three markers are Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2).

ER and PR testing determines whether breast cancer cells use the hormones estrogen and progesterone to grow. HER2 testing evaluates whether the cancer cells have increased levels of the HER2 protein or gene amplification. Together, these results help doctors understand the biological characteristics of the tumor, classify the cancer, estimate prognosis, and select appropriate treatment.

ER and PR are commonly assessed using immunohistochemistry (IHC), while HER2 may be assessed by IHC and, when required, confirmed with an additional test such as ISH/FISH.

This Test is Recommended for Individuals:

• Individuals with a newly diagnosed breast cancer
• Patients undergoing evaluation of a breast tumor or suspicious breast lesion
• Individuals with recurrent or metastatic breast cancer, when biomarker reassessment is clinically appropriate
• Patients whose healthcare provider needs to determine hormone receptor status
• Individuals being evaluated for suitability for hormone therapy
• Patients requiring assessment of HER2-targeted treatment eligibility
• Individuals undergoing comprehensive breast cancer profiling as recommended by their oncologist

FAQs

1. What do ER, PR, and HER2 mean?
ER stands for Estrogen Receptor, PR stands for Progesterone Receptor, and HER2 stands for Human Epidermal Growth Factor Receptor 2. These markers provide information about the characteristics of breast cancer cells and can influence treatment decisions.

2. Why are ER, PR, and HER2 tests important in breast cancer?
The results can help doctors determine whether a tumor is hormone-receptor positive or HER2-positive and guide treatment selection. For example, hormone-receptor-positive cancers may respond to endocrine therapy, while HER2-positive cancers may be considered for HER2-targeted treatment.

3. Does a positive ER, PR, or HER2 result mean the cancer is more severe?
Not necessarily. These markers describe the biology of the tumor rather than simply indicating how advanced the cancer is. Their results help doctors understand the cancer and select the most appropriate treatment. The overall outlook also depends on factors such as cancer stage, tumor characteristics, lymph-node involvement, and response to treatment.